Legal Representation
Attorney
Sandra J Wunderlich
USPTO Deadlines
Next Renewal Deadline
812 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-09-28)
Due Date
September 28, 2027
Grace Period Ends
March 28, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Sep 14, 2022 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Aug 12, 2022 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED |
| Aug 2, 2022 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Jul 7, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jul 7, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 7, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 7, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 7, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Mar 8, 2022 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED |
| Feb 9, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Feb 9, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Feb 9, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Feb 9, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 9, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Sep 28, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 24, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Aug 22, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Jul 28, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 27, 2021 | DPCC | D | DIVISIONAL PROCESSING COMPLETE |
| Jul 27, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| May 20, 2021 | INCD | O | ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST |
| May 20, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Apr 26, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Mar 29, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Mar 29, 2021 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED |
| Mar 29, 2021 | DRRR | I | DIVISIONAL REQUEST RECEIVED |
| Mar 29, 2021 | IUAF | S | USE AMENDMENT FILED |
| Mar 22, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 22, 2021 | EXT5 | S | SOU EXTENSION 5 FILED |
| Mar 22, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Sep 22, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 18, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Sep 18, 2020 | EXT4 | S | SOU EXTENSION 4 FILED |
| Sep 18, 2020 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Mar 10, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 7, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 7, 2020 | EXT3 | S | SOU EXTENSION 3 FILED |
| Mar 7, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Oct 3, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 1, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 1, 2019 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 1, 2019 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Mar 15, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 13, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 13, 2019 | EXT1 | S | SOU EXTENSION 1 FILED |
| Mar 13, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Oct 9, 2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Aug 14, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 14, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jul 25, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Detailed Classifications
Class 005
Prescription based pharmaceutical preparations for use in connection with humans for the prevention and treatment of oncological and rare diseases, disorders and conditions
First Use Anywhere:
Mar 1, 2019
First Use in Commerce:
Mar 1, 2019
Additional Information
Other
In the Statement, line 1, "Acrotech Biopharma, LLC" should be deleted, and, "Acrotech Biopharma LLC" should be inserted.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOPHARMA"